CVN766 – Selective Ox1R antagonist shows efficacy in pre-clinical models of schizophrenia
Nicola Brice(Covance (United Kingdom)), Mark Carlton(University of Cambridge), Anna Rowland(Covance (United Kingdom)), M. J. Hill(Takeda (United Kingdom)), Robert G. Newman(Takeda (United Kingdom)), Kathy Matthews(Covance (United Kingdom)), David Harrison(University of Notre Dame), A.C.A. Glen(Takeda (United Kingdom)), Louise Dickson(Takeda (United Kingdom)), Lee A. Dawson(Covance (United Kingdom)), Roland W. Bürli(Covance (United Kingdom))
Cited by 0
Related Papers
The <i>GPR54</i> Gene as a Regulator of Puberty
|New England Journal of Medicine|2003|2.5k
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
|Journal of Medicinal Chemistry|2023|62
Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing
|European Journal of Pharmacology|2014|54
Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796
|Journal of Pharmacology and Experimental Therapeutics|2024|51
Myocardial Hypertrophy Resulting from Low Dosage Isoproterenol Administration in Rats
|Experimental Biology and Medicine|1971|49